Pharmacokinetics and pharmacodynamics of amlodipine in hypertensive patients with type ii diabetes mellitus

Richard A Preston, M. Chung, M. Gaffney, A. Alonso, N. M. Baltodano, M. Epstein

Research output: Contribution to journalArticle

Abstract

Purpose: Because of the developing theoretical basis that diabetes mellitus (DM) and its complications may provoke important alterations of pharmacokinetics (PK) and pharmacodynamics (PD) of cardiovascular drugs [Diabetes Care 1999;22:982-8], we investigated the comparative PK and PD of amlodipine in hypertensive subjects with and without Type II DM. Methods: Design: Placebo wash-out, titration, and maintenance. Patients: 18 hypertensive patients with Type II DM and 10 nondiabetic hypertensive patients. AUC, Cmax, and Tmax were determined for amlodipine. Acute 24-hour PD response: blood pressure (BP) and telemetric heart rate (THR). Results: There were no significant differences between hypertensive subjects with and without DM for either amlodipine 5 or 10 mg in AUC (p=0.40 for 5 mg; p=0.59 for 10 mg), Cmax (p=0.41 for 5 mg; p=0.45 for 10 mg) and Tmax (p=0.79 for 5 mg; p=0.67 for 10 mg). The 24-hour BP and THR did not differ between diabetic and nondiabetic subjects. Conclusion: Our study provides a comprehensive data base clearly demonstrating that the diabetic milieu did not alter the pharmacokinetics or pharmacodynamics of amlodipine.

Original languageEnglish
JournalClinical Pharmacology and Therapeutics
Volume69
Issue number2
StatePublished - Dec 1 2001

Fingerprint

Amlodipine
Type 2 Diabetes Mellitus
Pharmacokinetics
Area Under Curve
Heart Rate
Blood Pressure
Cardiovascular Agents
Diabetes Complications
Diabetes Mellitus
Placebos
Maintenance
Databases

ASJC Scopus subject areas

  • Pharmacology

Cite this

Pharmacokinetics and pharmacodynamics of amlodipine in hypertensive patients with type ii diabetes mellitus. / Preston, Richard A; Chung, M.; Gaffney, M.; Alonso, A.; Baltodano, N. M.; Epstein, M.

In: Clinical Pharmacology and Therapeutics, Vol. 69, No. 2, 01.12.2001.

Research output: Contribution to journalArticle

@article{e9d79b8c5abc42e0bf0a92caa4e1b5a0,
title = "Pharmacokinetics and pharmacodynamics of amlodipine in hypertensive patients with type ii diabetes mellitus",
abstract = "Purpose: Because of the developing theoretical basis that diabetes mellitus (DM) and its complications may provoke important alterations of pharmacokinetics (PK) and pharmacodynamics (PD) of cardiovascular drugs [Diabetes Care 1999;22:982-8], we investigated the comparative PK and PD of amlodipine in hypertensive subjects with and without Type II DM. Methods: Design: Placebo wash-out, titration, and maintenance. Patients: 18 hypertensive patients with Type II DM and 10 nondiabetic hypertensive patients. AUC, Cmax, and Tmax were determined for amlodipine. Acute 24-hour PD response: blood pressure (BP) and telemetric heart rate (THR). Results: There were no significant differences between hypertensive subjects with and without DM for either amlodipine 5 or 10 mg in AUC (p=0.40 for 5 mg; p=0.59 for 10 mg), Cmax (p=0.41 for 5 mg; p=0.45 for 10 mg) and Tmax (p=0.79 for 5 mg; p=0.67 for 10 mg). The 24-hour BP and THR did not differ between diabetic and nondiabetic subjects. Conclusion: Our study provides a comprehensive data base clearly demonstrating that the diabetic milieu did not alter the pharmacokinetics or pharmacodynamics of amlodipine.",
author = "Preston, {Richard A} and M. Chung and M. Gaffney and A. Alonso and Baltodano, {N. M.} and M. Epstein",
year = "2001",
month = "12",
day = "1",
language = "English",
volume = "69",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics and pharmacodynamics of amlodipine in hypertensive patients with type ii diabetes mellitus

AU - Preston, Richard A

AU - Chung, M.

AU - Gaffney, M.

AU - Alonso, A.

AU - Baltodano, N. M.

AU - Epstein, M.

PY - 2001/12/1

Y1 - 2001/12/1

N2 - Purpose: Because of the developing theoretical basis that diabetes mellitus (DM) and its complications may provoke important alterations of pharmacokinetics (PK) and pharmacodynamics (PD) of cardiovascular drugs [Diabetes Care 1999;22:982-8], we investigated the comparative PK and PD of amlodipine in hypertensive subjects with and without Type II DM. Methods: Design: Placebo wash-out, titration, and maintenance. Patients: 18 hypertensive patients with Type II DM and 10 nondiabetic hypertensive patients. AUC, Cmax, and Tmax were determined for amlodipine. Acute 24-hour PD response: blood pressure (BP) and telemetric heart rate (THR). Results: There were no significant differences between hypertensive subjects with and without DM for either amlodipine 5 or 10 mg in AUC (p=0.40 for 5 mg; p=0.59 for 10 mg), Cmax (p=0.41 for 5 mg; p=0.45 for 10 mg) and Tmax (p=0.79 for 5 mg; p=0.67 for 10 mg). The 24-hour BP and THR did not differ between diabetic and nondiabetic subjects. Conclusion: Our study provides a comprehensive data base clearly demonstrating that the diabetic milieu did not alter the pharmacokinetics or pharmacodynamics of amlodipine.

AB - Purpose: Because of the developing theoretical basis that diabetes mellitus (DM) and its complications may provoke important alterations of pharmacokinetics (PK) and pharmacodynamics (PD) of cardiovascular drugs [Diabetes Care 1999;22:982-8], we investigated the comparative PK and PD of amlodipine in hypertensive subjects with and without Type II DM. Methods: Design: Placebo wash-out, titration, and maintenance. Patients: 18 hypertensive patients with Type II DM and 10 nondiabetic hypertensive patients. AUC, Cmax, and Tmax were determined for amlodipine. Acute 24-hour PD response: blood pressure (BP) and telemetric heart rate (THR). Results: There were no significant differences between hypertensive subjects with and without DM for either amlodipine 5 or 10 mg in AUC (p=0.40 for 5 mg; p=0.59 for 10 mg), Cmax (p=0.41 for 5 mg; p=0.45 for 10 mg) and Tmax (p=0.79 for 5 mg; p=0.67 for 10 mg). The 24-hour BP and THR did not differ between diabetic and nondiabetic subjects. Conclusion: Our study provides a comprehensive data base clearly demonstrating that the diabetic milieu did not alter the pharmacokinetics or pharmacodynamics of amlodipine.

UR - http://www.scopus.com/inward/record.url?scp=33748969856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748969856&partnerID=8YFLogxK

M3 - Article

VL - 69

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -